PCIDB

KNApSAcK Metabolite C00011322

Metabolite

KNApSAcK Entry

id C00011322
Name Phomin / Cytochalasin B
CAS RN 14930-96-2
Standard InChI InChI=1S/C29H37NO5/c1-18-9-7-13-22(31)15-16-25(32)35-29-23(14-8-10-18)27(33)20(3)19(2)26(29)24(30-28(29)34)17-21-11-5-4-6-12-21/h4-6,8,11-12,14-16,18-19,22-24,26-27,31,33H,3,7,9-10,13,17H2,1-2H3,(H,30,34)/b14-8+,16-15+/t18-,19-,22-,23+,24?,26?,27-,29-/m1/s1
Standard InChI (Main Layer) InChI=1S/C29H37NO5/c1-18-9-7-13-22(31)15-16-25(32)35-29-23(14-8-10-18)27(33)20(3)19(2)26(29)24(30-28(29)34)17-21-11-5-4-6-12-21/h4-6,8,11-12,14-16,18-19,22-24,26-27,31,33H,3,7,9-10,13,17H2,1-2H3,(H,30,34)

Cluster

Phytochemical cluster
KCF-S cluster No. 480

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL56897 CHEMBL411729 CHEMBL1422227 CHEMBL1554187

KEGG

By LinkDB C19954

CTD

By CAS RN D003571

Human Protein / Gene in interaction

20 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
Q16637 Survival motor neuron protein Unclassified protein CHEMBL1554187 CHEMBL1613842 (1)
4 / 2
Q9UIF8 Bromodomain adjacent to zinc finger domain protein 2B Unclassified protein CHEMBL1422227 CHEMBL1738312 (1)
0 / 0
Q99700 Ataxin-2 Unclassified protein CHEMBL56897 CHEMBL2114784 (1)
1 / 1
P27338 Amine oxidase [flavin-containing] B Oxidoreductase CHEMBL411729 CHEMBL965571 (1) CHEMBL965576 (1)
0 / 0
P02545 Prelamin-A/C Unclassified protein CHEMBL1422227 CHEMBL1614544 (1)
11 / 10
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL411729 CHEMBL965574 (1)
1 / 1
P20701 Integrin alpha-L Membrane receptor CHEMBL411729 CHEMBL982328 (1) CHEMBL982330 (1)
CHEMBL945484 (1) CHEMBL945487 (1)
CHEMBL1016754 (1) CHEMBL1016757 (1)
0 / 0
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL1554187 CHEMBL1794584 (1)
2 / 0
O75496 Geminin Unclassified protein CHEMBL56897 CHEMBL1554187 CHEMBL2114843 (2) CHEMBL2114780 (2)
0 / 0
P51151 Ras-related protein Rab-9A Unclassified protein CHEMBL1422227 CHEMBL1613838 (1)
0 / 0
P43220 Glucagon-like peptide 1 receptor Glucagon-like peptide receptor CHEMBL1554187 CHEMBL2114788 (1)
0 / 0
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL1554187 CHEMBL1794401 (1)
0 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL1422227 CHEMBL1614521 (1)
0 / 0
O15118 Niemann-Pick C1 protein Unclassified protein CHEMBL1422227 CHEMBL1614342 (1)
1 / 1
Q9UNA4 DNA polymerase iota Enzyme CHEMBL1554187 CHEMBL1794483 (1)
0 / 0
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL56897 CHEMBL1554187 CHEMBL1738184 (3)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL1554187 CHEMBL1738442 (1)
0 / 0
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic Enzyme CHEMBL56897 CHEMBL1554187 CHEMBL2354311 (2)
1 / 0
P01215 Glycoprotein hormones alpha chain Unclassified protein CHEMBL56897 CHEMBL2114913 (1)
0 / 3
Q06710 Paired box protein Pax-8 Unclassified protein CHEMBL56897 CHEMBL2354301 (1)
1 / 2

CTD interaction (29)

compound gene gene name gene description interaction interaction type form reference
pmid
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 [Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK1 protein affects cotreatment
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 [Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK3 protein affects cotreatment
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 [Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein affects cotreatment
/ increases secretion
protein 18776917
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 Dexamethasone analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 18776917
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK1 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 727 C5
C5a
C5b
CPAMD4
complement component 5 resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 18776917
D003571 847 CAT
catalase (EC:1.11.1.6) Cytochalasin B inhibits the reaction [Dehydroascorbic Acid results in increased expression of CAT protein] decreases reaction
/ increases expression
protein 20166893
D003571 1437 CSF2
GMCSF
colony stimulating factor 2 (granulocyte-macrophage) Cytochalasin B inhibits the reaction [kaempferol results in increased secretion of CSF2 protein] decreases reaction
/ increases secretion
protein 18346843
D003571 1437 CSF2
GMCSF
colony stimulating factor 2 (granulocyte-macrophage) Cytochalasin B inhibits the reaction [Quercetin results in increased secretion of CSF2 protein] decreases reaction
/ increases secretion
protein 18346843
D003571 1991 ELANE
ELA2
GE
HLE
HNE
NE
PMN-E
SCN1
elastase, neutrophil expressed (EC:3.4.21.37) [Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein affects cotreatment
/ increases secretion
protein 19686721
D003571 1991 ELANE
ELA2
GE
HLE
HNE
NE
PMN-E
SCN1
elastase, neutrophil expressed (EC:3.4.21.37) pirinixic acid analog inhibits the reaction [[Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 19686721
D003571 2056 EPO
EP
MVCD2
erythropoietin [Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein affects cotreatment
/ increases secretion
protein 18776917
D003571 2056 EPO
EP
MVCD2
erythropoietin [Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein affects cotreatment
/ increases secretion
protein 18776917
D003571 2056 EPO
EP
MVCD2
erythropoietin Dexamethasone analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 18776917
D003571 2056 EPO
EP
MVCD2
erythropoietin resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 18776917
D003571 2056 EPO
EP
MVCD2
erythropoietin resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 18776917
D003571 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Cytochalasin B inhibits the reaction [[Alum Compounds co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17404311
D003571 3567 IL5
EDF
IL-5
TRF
interleukin 5 (colony-stimulating factor, eosinophil) [Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein affects cotreatment
/ increases secretion
protein 18776917
D003571 3567 IL5
EDF
IL-5
TRF
interleukin 5 (colony-stimulating factor, eosinophil) resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 18776917
D003571 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK1 protein affects cotreatment
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK1 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK3 protein affects cotreatment
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased phosphorylation of and results in increased activity of MAPK3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 18776917
D003571 6513 SLC2A1
DYT17
DYT18
DYT9
EIG12
GLUT
GLUT1
GLUT1DS
HTLVR
PED
solute carrier family 2 (facilitated glucose transporter), member 1 Cytochalasin B affects the folding of SLC2A1 protein affects folding
protein 22363641
D003571 6513 SLC2A1
DYT17
DYT18
DYT9
EIG12
GLUT
GLUT1
GLUT1DS
HTLVR
PED
solute carrier family 2 (facilitated glucose transporter), member 1 Cytochalasin B inhibits the reaction [SLC2A1 protein results in increased transport of Glucose] decreases reaction
/ increases transport
protein 8457197
D003571 6514 SLC2A2
GLUT2
solute carrier family 2 (facilitated glucose transporter), member 2 Cytochalasin B inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose] decreases reaction
/ increases transport
protein 8457197
D003571 6515 SLC2A3
GLUT3
solute carrier family 2 (facilitated glucose transporter), member 3 Cytochalasin B inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose] decreases reaction
/ increases transport
protein 8457197
D003571 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Cytochalasin B inhibits the reaction [Dehydroascorbic Acid results in increased expression of SOD2 protein] decreases reaction
/ increases expression
protein 20166893

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (22)

OMIM preferred title UniProt
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#114500 Colorectal cancer; crc P84022
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#137800 Glioma susceptibility 1; glm1 O75874
#610140 Heart-hand syndrome, slovenian type P02545
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#218700 Hypothyroidism, congenital, nongoitrous, 2; chng2 Q06710
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#257220 Niemann-pick disease, type c1; npc1 O15118
#275210 Restrictive dermopathy, lethal P02545
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#183090 Spinocerebellar ataxia 2; sca2 Q99700

KEGG DISEASE (18)

KEGG disease name UniProt
H00136 Niemann-Pick disease type C (NPC) O15118 (related)
H00081 Hashimoto's thyroiditis P01215 (marker)
H00082 Graves' disease P01215 (marker)
H00250 Congenital nongoitrous hypothyroidism (CHNG) P01215 (marker)
Q06710 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00548 Brunner syndrome P21397 (related)
H00032 Thyroid cancer Q06710 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)